

672,317

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptaul82das

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
 NEWS 2 "Ask CAS" for self-help around the clock
 NEWS 3 SEP 01 New pricing for the Save Answers for SciFinder Wizard within
 STN Express with Discover!
 NEWS 4 OCT 28 KOREAPAT now available on STN
 NEWS 5 NOV 30 PHAR reloaded with additional data
 NEWS 6 DEC 01 LISA now available on STN
 NEWS 7 DEC 09 12 databases to be removed from STN on December 31, 2004
 NEWS 8 DEC 15 MEDLINE update schedule for December 2004
 NEWS 9 DEC 17 ELCOM reloaded; updating to resume; current-awareness
 alerts (SDIs) affected
 NEWS 10 DEC 17 COMPUAB reloaded; updating to resume; current-awareness
 alerts (SDIs) affected
 NEWS 11 DEC 17 SOLIDSTATE reloaded; updating to resume; current-awareness
 alerts (SDIs) affected
 NEWS 12 DEC 17 CERAB reloaded; updating to resume; current-awareness
 alerts (SDIs) affected
 NEWS 13 DEC 17 THREE NEW FIELDS ADDED TO IFIPAT/IFIUDB/IFICDB
 NEWS 14 DEC 30 EPFULL: New patent full text database to be available on STN
 NEWS 15 DEC 30 CAPLUS - PATENT COVERAGE EXPANDED
 NEWS 16 JAN 03 No connect-hour charges in EPFULL during January and
 February 2005
 NEWS 17 FEB 25 CA/CAPLUS - Russian Agency for Patents and Trademarks
 (ROSPATENT) added to list of core patent offices covered
 NEWS 18 FEB 10 STN Patent Forums to be held in March 2005
 NEWS 19 FEB 16 STN User Update to be held in conjunction with the 229th ACS
 National Meeting on March 13, 2005
 NEWS 20 FEB 28 PATDPAFULL - New display fields provide for legal status
 data from INPADOC
 NEWS 21 FEB 28 BABS - Current-awareness alerts (SDIs) available
 NEWS 22 FEB 28 MEDLINE/LMEDLINE reloaded
 NEWS 23 MAR 02 GBFULL: New full-text patent database on STN
 NEWS 24 MAR 03 REGISTRY/ZREGISTRY - Sequence annotations enhanced
 NEWS 25 MAR 03 MEDLINE file segment of TOXCENTER reloaded

 NEWS EXPRESS JANUARY 10 CURRENT WINDOWS VERSION IS V7.01a, CURRENT
 MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
 AND CURRENT DISCOVER FILE IS DATED 10 JANUARY 2005

 NEWS HOURS STN Operating Hours Plus Help Desk Availability
 NEWS INTER General Internet Information
 NEWS LOGIN Welcome Banner and News Items
 NEWS PHONE Direct Dial and Telecommunication Network Access to STN
 NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 09:28:21 ON 07 MAR 2005

=> FIL STNGUIDE

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'STNGUIDE' ENTERED AT 09:28:41 ON 07 MAR 2005

USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT

COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE

AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.

LAST RELOADED: Mar 4, 2005 (20050304/UP) .

=> file ca biosis medline

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.06

0.27

FILE 'CA' ENTERED AT 09:29:27 ON 07 MAR 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 09:29:27 ON 07 MAR 2005

Copyright (c) 2005 The Thomson Corporation

FILE 'MEDLINE' ENTERED AT 09:29:27 ON 07 MAR 2005

=> e collins daniel

E1	2	COLLINOVA/BI
E2	6005	COLLINS/BI
E3	0 -->	COLLINS DANIEL/BI
E4	4	COLLINS3/BI
E5	2	COLLINS4/BI
E6	5	COLLINSA/BI
E7	27	COLLINSAE/BI
E8	1	COLLINSCRAFT/BI
E9	58	COLLINSELLA/BI
E10	1	COLLINSET/BI
E11	50	COLLINSI/BI
E12	113	COLLINSIA/BI

=> e collins daniel/au

E1	1	COLLINS DANA R/AU
E2	1	COLLINS DANA ROSE/AU
E3	10 -->	COLLINS DANIEL/AU
E4	5	COLLINS DANIEL A/AU
E5	4	COLLINS DANIEL E/AU
E6	2	COLLINS DANIEL EDWARD/AU
E7	10	COLLINS DANIEL J/AU
E8	1	COLLINS DANIEL JOHN/AU
E9	5	COLLINS DANIEL L/AU
E10	14	COLLINS DANIEL P/AU
E11	1	COLLINS DANIEL PATRICK/AU
E12	2	COLLINS DANIEL R/AU

=> s e3 or e10

L1 24 "COLLINS DANIEL"/AU OR "COLLINS DANIEL P"/AU

=> e collins d/au

E1	1	COLLINS CYRIL/AU
E2	1	COLLINS CYRIL A/AU
E3	352 -->	COLLINS D/AU
E4	197	COLLINS D A/AU

E5	10	COLLINS D ANTHONY/AU
E6	8	COLLINS D B/AU
E7	443	COLLINS D C/AU
E8	1	COLLINS D CLAY/AU
E9	10	COLLINS D D/AU
E10	2	COLLINS D DIXON/AU
E11	31	COLLINS D E/AU
E12	54	COLLINS D F/AU

```
=> s e3
L2      352 "COLLINS D"/AU
```

```
=> s collins d p/au
L3      31 COLLINS D P/AU
```

```
=> e hapke joel/au
E1      21      HAPKE J/AU
E2      18      HAPKE JOBST/AU
E3      0  --> HAPKE JOEL/AU
E4      3      HAPKE JOEL H/AU
E5      2      HAPKE JOERG/AU
E6     151      HAPKE M/AU
E7      10      HAPKE M R/AU
E8      5      HAPKE MANFRED/AU
E9      5      HAPKE MARC R/AU
E10     5      HAPKE MARKO/AU
E11     2      HAPKE MICHAEL/AU
E12    37      HAPKE P/AU
```

```
=> s e1 or e3
L4      21 "HAPKE J"/AU OR "HAPKE JOEL"/AU
```

```
=> e buchert carol/au
E1      1      BUCHERT BETSY/AU
E2      3      BUCHERT C/AU
E3      0  --> BUCHERT CAROL/AU
E4      1      BUCHERT CAROL A/AU
E5      1      BUCHERT CH/AU
E6      3      BUCHERT DAGOBERT/AU
E7      6      BUCHERT E/AU
E8      1      BUCHERT E D/AU
E9      1      BUCHERT E J/AU
E10     2      BUCHERT E T/AU
E11     2      BUCHERT ELAINE/AU
E12     4      BUCHERT ELAINE T/AU
```

```
=> s e2 or e4
L5      4 "BUCHERT C"/AU OR "BUCHERT CAROL A"/AU
```

```
=> s hapke joel h/au
L6      3 HAPKE JOEL H/AU
```

```
=> s l1 or l2 or l3 or l4 or l5 or l6
L7     432 L1 OR L2 OR L3 OR L4 OR L5 OR L6
```

```
=> s cd94
L8     1496 CD94
```

```
=> s cd161
L9     470 CD161
```

```
=> s l8 and l9
L10    131 L8 AND L9
```

```
=> s l7 and l10
L11     1 L7 AND L10
```

```
=> d l11 bib
```

L11 ANSWER 1 OF 1 CA COPYRIGHT 2005 ACS on STN
 AN 140:283944 CA
 TI Methods for separating cells by agglutinating cells via cell surface
 antigen recognition
 IN Collins, Daniel P.; Hapke, Joel H.; Buchert,
 Carol A.
 PA USA
 SO U.S. Pat. Appl. Publ., 16 pp.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004062766	A1	20040401	US 2003-672317	20030926
	WO 2004029208	A2	20040408	WO 2003-US30265	20030926
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				
	CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,				
	GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,				
	LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ,				
	OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,				
	TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,				
	KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,				
	FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,				
	BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI	US 2002-414692P	P	20020927		

=> s t(W) (cell or lymphocyte)
 L12 655059 T(W) (CELL OR LYMPHOCYTE)

=> s l10 and l12
 L13 83 L10 AND L12

=> s (isolat? or separat? or purif? or prepar?) (5a) l12
 L14 25375 (ISOLAT? OR SEPARAT? OR PURIF? OR PREPAR?) (5A) L12

=> l10 and l14
 L10 IS NOT A RECOGNIZED COMMAND
 The previous command name entered was not recognized by the system.
 For a list of commands available to you in the current file, enter
 "HELP COMMANDS" at an arrow prompt (=>).

=> s l10 and l14
 L15 3 L10 AND L14

=> duplicate remove
 ENTER L# LIST OR (END): l15
 PROCESSING COMPLETED FOR L15
 L16 3 DUPLICATE REMOVE L15 (0 DUPLICATES REMOVED)

=> d l16 bib ab 1-3

L16 ANSWER 1 OF 3 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
 AN 2003:357970 BIOSIS
 DN PREV200300357970
 TI Zoledronic Acid Is More Effective in Stimulating gammadelta T Cells Than
 Pamidronate.
 AU Baker, Jeanette [Reprint Author]; Verneris, Michael R. [Reprint Author];
 Schimmelpfennig, Christoph H. [Reprint Author]; Negrin, Robert S. [Reprint
 Author]
 CS Bone Marrow Transplantation, Stanford University, Stanford, CA, USA
 SO Blood, (November 16 2002) Vol. 100, No. 11, pp. Abstract No. 3699. print.
 Meeting Info.: 44th Annual Meeting of the American Society of Hematology.
 Philadelphia, PA, USA. December 06-10, 2002. American Society of
 Hematology.
 CODEN: BLOOAW. ISSN: 0006-4971.
 DT Conference; (Meeting)

Conference; Abstract; (Meeting Abstract)
Conference; (Meeting Poster)

LA English

ED Entered STN: 6 Aug 2003

Last Updated on STN: 6 Aug 2003

AB Stimulation of peripheral blood lymphocytes with pamidronate and IL-2 is known to induce gammadelta T cell expansion and activation. Zoledronic acid is a newer aminobisphosphonate which has recently been FDA approved. While zoledronic acid is more potent at inhibiting bone reabsorption nothing is known about its ability to stimulate gammadelta T cells. Here, we compared the effects of zoledronic acid with pamidronate on gammadelta T cell activation, expansion, and antitumor activity. PBMC from healthy donors were cultured with either pamidronate (40mM) or zoledronic acid (1mM) on day 0 with either high (300IU/ml) or low (10IU/ml) dose IL-2. Both types of aminobisphosphonates yielded a substantial increase in the total of number of cultured cells over 14-21 days. In the low dose IL-2 groups there were considerable differences in the fold expansion in the total number of cells (pamidronate 5x vs. zoledronic acid 15x). Differences in the high dose IL-2 groups were less remarkable (pamidronate 16x vs. zoledronic acid 20x). Under both IL-2 conditions the viability of the zoledronic acid stimulated cells was consistently higher than that of pamidronate. FACS analysis showed that zoledronic acid yielded higher percentages of gammadelta TCR+ cells after 7-14 days (apprx50-60% for pamidronate vs. apprx70-90% for zoledronic acid). Kinetic analysis of the gammadelta T cell expansion over time revealed substantial differences with the different aminobisphosphonates such that the gammadelta T cells in the zoledronic acid group expanded more rapidly than cells stimulated with pamidromate. FACS analysis at day 14-21 revealed that both groups of expanded cells were similar, with >90% of gammadelta T cells being Vgamma9+Vdelta2+ and the majority were CD4-CD8-. Multicolor FACS analysis showed that freshly **isolated** gammadelta T cells did not express activation (CD25, CD69, CD11a) or NK cell (CD56, **CD161**, **CD94**) markers, whereas >50% of the expanded gammadelta T cells expressed these receptors. There was no consistent difference in the phenotype for cells expanded with either bisphosphonate. Cytotoxicity was studied against the plasmacytoma cell lines RPMI 8226 and U266. Freshly **isolated** peripheral blood gammadelta T cells had no cytolytic activity, but by day 7-14 of culture, **purified** gammadelta T cells had 50-70% specific lysis against these targets (E:T=40:1). Recently studies have shown that NKG2D can act as a costimulatory receptor and reduce gammadelta TCR signaling threshold. We found that nearly all expanded gammadelta T cells expressed NKG2D and that blocking this molecule reduced cytotoxicity by apprx30-40%. Collectively, these studies show that both pamidronate and zoledronic acid induce gammadelta T cell expansion and proliferation, but that stimulation with zoledronic acid leads to a more rapid increase in the number of gammadelta T cells with an earlier onset in cytotoxicity as compared to pamidronate. Such information may be critical in the planning of studies using ex vivo expanded and activated gammadelta T cells.

L16 ANSWER 2 OF 3 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN

AN 2002:153159 BIOSIS

DN PREV200200153159

TI Bisphosphonate and IPP expanded gammadelta T cells have in vitro and in vivo antitumor function.

AU Baker, Jeanette [Reprint author]; Verneris, Michael R. [Reprint author]; Kivivuori, Sanna M. [Reprint author]; Schimmelpfennig, Christoph H. [Reprint author]; Negrin, Robert S. [Reprint author]

CS Bone Marrow Transplantation, Stanford University, Stanford, CA, USA

SO Blood, (November 16, 2001) Vol. 98, No. 11 Part 1, pp. 167a. print.

Meeting Info.: 43rd Annual Meeting of the American Society of Hematology, Part 1. Orlando, Florida, USA. December 07-11, 2001. American Society of Hematology.

CODEN: BLOOAW. ISSN: 0006-4971.

DT Conference; (Meeting)

Conference; Abstract; (Meeting Abstract)

Conference; (Meeting Poster)

LA English

ED Entered STN: 21 Feb 2002

Last Updated on STN: 26 Feb 2002

AB The use of bisphosphonates in patients with MM reduces skeletal complications. Recent studies have shown that bisphosphonates are structurally similar to isopentenyl pyrophosphate (IPP) which is a putative ligand recognized by Vgamma9Vdelta2 gammadelta T cells, such cells may mediate antitumor activity. We evaluated the effects of bisphosphonates and IPP on gammadelta T cell expansion, phenotype, cytokine production and antitumor cytotoxicity. PBMC from 14 healthy donors were cultured with pamidronate, IPP and the non-aminobisphosphonate etidronate with 300IU of IL2/ml. After 7-14 days in culture with IPP or pamidronate 50-70% of the T cells expressed the gammadelta T cell receptor as compared to cells that were cultured with etidronate or IL2 alone where <5% of the cells were gammadelta T cells. The gammadelta T cells expanded between 30-500 fold under these culture conditions. Cytokine production over time in culture revealed high basal secretion of IFNgamma and IL-5 at days 14-21 of culture, where as IL2 secretion was noted beyond day 21. Minimal to no IL-4, IL-10 or TNFalpha were secreted. FACS analysis showed that (>90%) of gammadelta T cells expressed the Vgamma9Vdelta2 receptor, with the majority being CD4-CD8- double negative, and less than 10% expressing either CD8+ or CD4+. Interestingly 15-26% were CD4+CD8+ double positive. Cytotoxicity was studied against the cell lines RPMI 8226, U266, Daudi, HELA and MC-IXC. No cytolytic activity was observed at the initiation of culture but by 7-14 days the cells had 50-70% specific lysis against these cell lines at an E:T of 40:1. MACS **separated** gammadelta+ T cells had higher lytic ability against the tumor cell lines than the gammadelta- T cells. Multicolor FACS analysis show that the expanded gammadelta T cells are a heterogeneous population expressing a variety of molecules including CD2, CD56, **CD161**, **CD94**, CD69, CD25 and CD11a. gammadelta T cells expressing NK and activation markers had enhanced cytotoxicity. To further test the efficacy of gammadelta T cell in vivo, a sensitive bioluminescent assay for tumor growth and response to therapy was utilized. In preliminary experiments luciferase transfected MC-IXC and SK-OV-3 (5X104) were injected into SCID mice. 72 hours later pure gammadelta T cells (>97%) were injected (7.5X106). gammadelta T cell treated animals bearing the MC-IXC but not SK-OV-3 tumors had markedly reduced tumor signal and enhanced survival as compared to PBS treated animals. These data demonstrate that gammadelta T cells are readily expandable and have both in vitro and in vivo activity.

L16 ANSWER 3 OF 3 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN

AN 2001:311322 BIOSIS

DN PREV200100311322

TI The NK associated **CD94** C-type lectin is expressed in T-large granular lymphoproliferative disorders (T-LGLP).

AU Leymarie, V. [Reprint author]; Mauvieux, L. [Reprint author]; Delabesse, E. [Reprint author]; Hermine, O. [Reprint author]; Valensi, F. [Reprint author]; Cerf-Bensussan, N. [Reprint author]; Macintyre, E. A. [Reprint author]

CS Laboratoire Central d'Hematologie, Service Clinique d'Hematologie, Inserm E9925, Hopital Necker, Paris, France

SO Blood, (November 16, 2000) Vol. 96, No. 11 Part 2, pp. 41b. print. Meeting Info.: 42nd Annual Meeting of the American Society of Hematology. San Francisco, California, USA. December 01-05, 2000. American Society of Hematology.

CODEN: BLOOAW. ISSN: 0006-4971.

DT Conference; (Meeting)

Conference; Abstract; (Meeting Abstract)

LA English

ED Entered STN: 27 Jun 2001

Last Updated on STN: 19 Feb 2002

AB T large granular lymphoproliferative diseases (T-LGLP) are heterogeneous, but represent a clinically, morphologically and immunologically distinct disorder. They usually express CD3, abTCR, CD8 and CD57 but have also been shown to variably express the NK associated CD16 and/or CD56 antigens. In order to determine whether T-LGLP demonstrate other characteristics of NK cells, we analysed expression of KIR and NK antigens (CD158a, CD158b, p70, p140, Pen5, **CD161**, **CD94** and

NKG2A) by flow cytometry. Nine patients were studied: they had a chronic clinical course. Half presented neutropenia. We demonstrate by flow cytometry **CD94** positivity in 8/9 proliferations. The only **CD94** negative patient was the single case expressing both CD4 and CD8. **CD94** fluorescence intensity was variable from one patient to another but this did not correlate with neutropenia, clinical course or the expression of other cell surface markers. Lectin-like NK receptors are composed of the invariant **CD94** antigen associated with a variety of inhibitory or stimulatory NKG2 molecules. The mAb Z199, which recognises the NKG2A inhibitory isoform, was negative in all T-LGLP but identified a discrete subset of PBL in healthy control. In 3/3 cases, in **separated LGL-T cells**, RT-PCR confirmed the presence of **CD94** and the absence of NKG2A and NKG2B transcripts. In contrast, other KIR receptors, Pen5 and **CD161** expression was very heterogeneous and did not allow subdivision of this limited series. Our results demonstrate that **CD94** but not NKG2A can be added to the list of NK associated (although not restricted) markers which are expressed by T-LGLP. Unlike CD16 and CD56, **CD94** is expressed by the majority of our cases. IL-15 has recently been shown to modulate **CD94** expression, at least in vitro. It also triggers proliferation and cytotoxicity of T-LGLP. It is possible that IL-15 is implicated in the activation of these proliferations via its interaction with **CD94** and a NKG2 other than NKG2A and NKG2B. Even if we could not distinguish between a de novo expression of **CD94** on LGL-T or a selective expansion of **CD94**+T cells in T-LGLP, our data suggest that **CD94**/NKG2 expression may play a central role in the physiopathology of T-LGLP. Further analysis of these receptors will contribute to a better understanding of T-LGLP.

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

51.74

52.01

STN INTERNATIONAL LOGOFF AT 09:42:04 ON 07 MAR 2005

10/672,317

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	255	(424/93.71).CCLS.	US-PGPUB; USPAT; EPO; DERWENT	OR	OFF	2005/03/07 08:14
L2	2734	(435/7.23).CCLS.	US-PGPUB; USPAT; EPO; DERWENT	OR	OFF	2005/03/07 08:14
L3	922	(435/7.24).CCLS.	US-PGPUB; USPAT; EPO; DERWENT	OR	OFF	2005/03/07 08:14
L4	373	(435/7.25).CCLS.	US-PGPUB; USPAT; EPO; DERWENT	OR	OFF	2005/03/07 08:14
L5	114	(435/355).CCLS.	US-PGPUB; USPAT; EPO; DERWENT	OR	OFF	2005/03/07 08:14
L6	1013	(435/372).CCLS.	US-PGPUB; USPAT; EPO; DERWENT	OR	OFF	2005/03/07 08:14
L7	56	(435/372.1).CCLS.	US-PGPUB; USPAT; EPO; DERWENT	OR	OFF	2005/03/07 08:14
L8	88	(435/372.2).CCLS.	US-PGPUB; USPAT; EPO; DERWENT	OR	OFF	2005/03/07 08:14
L9	255	(435/372.3).CCLS.	US-PGPUB; USPAT; EPO; DERWENT	OR	OFF	2005/03/07 08:14
L10	5131	L1 or L2 or L3 or L4 or L5 or L6 or L7 or L8 or L9	US-PGPUB; USPAT; EPO; DERWENT	ADJ	ON	2005/03/07 08:14
L11	880	glycophorin	US-PGPUB; USPAT; EPO; DERWENT	ADJ	ON	2005/03/07 08:15
L12	2	107FMN	US-PGPUB; USPAT; EPO; DERWENT	ADJ	ON	2005/03/07 08:15

L13	0	YTH89	US-PGPUB; USPAT; EPO; DERWENT	ADJ	ON	2005/03/07 08:15
L14	2	"YTH89.1"	US-PGPUB; USPAT; EPO; DERWENT	ADJ	ON	2005/03/07 08:15
L15	16499	E4	US-PGPUB; USPAT; EPO; DERWENT	ADJ	ON	2005/03/07 08:15
L16	17331	L11 OR L12 OR L13 OR L14 OR L15	US-PGPUB; USPAT; EPO; DERWENT	ADJ	ON	2005/03/07 08:15
L17	237821	AGGLUTINAT\$8 OR CLUMP\$4 OR AGGREGAT\$8	US-PGPUB; USPAT; EPO; DERWENT	ADJ	ON	2005/03/07 08:15
L18	61486	DEXTRAN	US-PGPUB; USPAT; EPO; DERWENT	ADJ	ON	2005/03/07 08:16
L19	103	I10 and I16 and I17 and I18	US-PGPUB; USPAT; EPO; DERWENT	ADJ	ON	2005/03/07 08:18

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	205	CD94	US-PGPUB; USPAT; EPO; DERWENT	ADJ	ON	2005/03/07 08:55
L2	20	KP43	US-PGPUB; USPAT; EPO; DERWENT	ADJ	ON	2005/03/07 08:56
L3	8	KP ADJ "43"	US-PGPUB; USPAT; EPO; DERWENT	ADJ	ON	2005/03/07 08:56
L4	167	NKG2	US-PGPUB; USPAT; EPO; DERWENT	ADJ	ON	2005/03/07 08:56
L5	0	NKG ADJ 2	US-PGPUB; USPAT; EPO; DERWENT	ADJ	ON	2005/03/07 08:56
L6	274	L1 OR L2 OR L3 OR L4	US-PGPUB; USPAT; EPO; DERWENT	ADJ	ON	2005/03/07 08:57
L7	42	CD161	US-PGPUB; USPAT; EPO; DERWENT	ADJ	ON	2005/03/07 08:57
L8	25	NKR ADJ P1?	US-PGPUB; USPAT; EPO; DERWENT	ADJ	ON	2005/03/07 08:57
L9	62	L7 OR L8	US-PGPUB; USPAT; EPO; DERWENT	ADJ	ON	2005/03/07 08:58
L10	29	L6 AND L9	US-PGPUB; USPAT; EPO; DERWENT	ADJ	ON	2005/03/07 08:58
L11	255	(424/93.71).CCLS.	US-PGPUB; USPAT; EPO; DERWENT	OR	OFF	2005/03/07 08:58
L12	2734	(435/7.23).CCLS.	US-PGPUB; USPAT; EPO; DERWENT	OR	OFF	2005/03/07 08:58

L13	922	(435/7.24).CCLS.	US-PGPUB; USPAT; EPO; DERWENT	OR	OFF	2005/03/07 08:58
L14	373	(435/7.25).CCLS.	US-PGPUB; USPAT; EPO; DERWENT	OR	OFF	2005/03/07 08:58
L15	114	(435/355).CCLS.	US-PGPUB; USPAT; EPO; DERWENT	OR	OFF	2005/03/07 08:58
L16	1013	(435/372).CCLS.	US-PGPUB; USPAT; EPO; DERWENT	OR	OFF	2005/03/07 08:58
L17	56	(435/372.1).CCLS.	US-PGPUB; USPAT; EPO; DERWENT	OR	OFF	2005/03/07 08:58
L18	88	(435/372.2).CCLS.	US-PGPUB; USPAT; EPO; DERWENT	OR	OFF	2005/03/07 08:58
L19	255	(435/372.3).CCLS.	US-PGPUB; USPAT; EPO; DERWENT	OR	OFF	2005/03/07 08:58
L20	5131	L11 or L12 or L13 or L14 or L15 or L16 or L17 or L18 or L19	US-PGPUB; USPAT; EPO; DERWENT	ADJ	ON	2005/03/07 08:59
L21	3	L10 AND L20	US-PGPUB; USPAT; EPO; DERWENT	ADJ	ON	2005/03/07 08:59